Latest news for Favo Capital (OTC:FAVO) Stock

Favo Capital Inc is a direct funding company, which provides customized, short-term funding to small and mid-sized businesses nationwide. The company is also engaged in the real estate holdings division.

News

Movers & Shakers

Intraday Update

Markets

General

ACNNF

AESE

AFTM

ASCENDANT RES INC ORD by Ascendant Resources Inc.

ASDRF

ASHXF

ARTEMIS THERAPEUTICS INC by Artemis Therapeutics, Inc.

ATMS

BSAC

BWLVF

CADMF

CAMZF

CAPR

CFWFF

CHLKF

CLPHY

CLXT

CRLI

CRPOF

CTRA

DIDAY

DRRSF

ENDV

ETST

EVAHF

EXTN

FAVO

FLOOF

GLRI

GOTRF

GWEFF

ICOA

IDRA

IMMR

INCAF

INDXF

INPX

IRBT

ISRJF

LKSD

LORL

MAYNF

MMJFF

MMNFF

MRTMF

MTFBF

NAII

NKRKF

NRGMF

NSCO

NTGN

NWKFF

OSTK

OWCP

PHVAF

PREA

RAIL

RASFQ

RCKHF

RDWD

RITE

SARSF

SFET

SNNAF

SPLIF

SRAX

SRCAF

SYAAF

TIGR

TTMZF

UVSE

VICA

TPHS

BMIN

RAIO

AXPWQ

Stocks That Hit 52-Week Lows On Friday

Favo Capital Inc

KB Home (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KBH#NYSE">KBH</a>) will release earnings results for its third quarter, after the <a href="https://www.benzinga.com/quote/KBH/earnings">closing bell on Tuesday</a>.
Analysts expect the Los Angeles-based company to report quarterly earnings at $2.06 per share. That&#8217;s up from $1.80 per share in the year-ago period. KB Home projects quarterly revenue of $1.73 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
On Sept. 19, Bank of America Securities analyst Rafe Jadrosich maintained KB Home with a Neutral rating and raised the price target from $75 to $90.
With the recent buzz around KB Home, some investors may be eyeing potential gains from the company's dividends. As of now, KB Home has a dividend yield of 1.15%. That&#8217;s a quarterly dividend amount of 25 cents a share ($1.00 a year).
To figure out how to earn $500 monthly from KB Home, we start with the yearly target of $6,000 ($500 x 12 months).
Next, we take this amount and divide it by KB Home's $1.00 dividend: $6,000 / $1.00 = 6,000 shares
So, an investor would need to own approximately $523,380 worth of KB Home, or 6,000 shares to generate a monthly dividend income of $500.
Assuming a more conservative goal of $100 monthly ($1,200 annually), we do the same calculation: $1,200 / $1.00 = 1,200 shares, or $104,676 to generate a monthly dividend income of $100.
Note that dividend yield can change on a rolling basis, as the dividend payment and the stock price both fluctuate over time.
The dividend yield is calculated by dividing the annual dividend payment by the current stock price. As the stock price changes, the dividend yield will also change.
For example, if a stock pays an annual dividend of $2 and its current price is $50, its dividend yield would be 4%. However, if the stock price increases to $60, the dividend yield would decrease to 3.33% ($2/$60).
Conversely, if the stock price decreases to $40, the dividend yield would increase to 5% ($2/$40).
Further, the dividend payment itself can also change over time, which can also impact the dividend yield. If a company increases its dividend payment, the dividend yield will increase even if the stock price remains the same. Similarly, if a company decreases its dividend payment, the dividend yield will decrease.
KBH Price Action: Shares of KB Home fell 2.6% to close at $87.23 on Friday.
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>
Image: Shutterstock

Earnings

Long Ideas

Trading Ideas

How To Earn $500 A Month From KB Home Stock Ahead Of Q3 Earnings

Macro Economic Events

Economics

Federal Reserve

Fed's Kashkari Says Penciled In 50 Basis Points More Cuts In 2024

AirBaltic Signs Long-Term EngineWise Maintenance Agreement With Pratt & Whitney For GTF Engine Fleet, Linking Costs To Engine Utilization

Biotech

LTRN

Lantern Pharma Receives Three FDA Rare Pediatric Disease Designations For LP-184 In Malignant Rhabdoid Tumors, Rhabdomyosarcoma, And Hepatoblastoma, Bringing Total To Four RPDDs

WIIM

SPRC

SciSparc shares are trading higher after the company received FDA approval to initiate a Phase IIb clinical trial of SCI-110 for the treatment of Tourette syndrome.

Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>)&nbsp;("Gorilla" or the "Company") and CS Energy Technology Co., Ltd., one of Asia's leading energy infrastructure providers, have announced a strategic cooperation agreement. This collaboration marks a transformative step in developing innovative solutions for smart and green cities across Thailand and Southeast Asia to shape a sustainable future.

Global

GRRR

Gorilla Technology And CS Energy Form AI-Powered Strategic Partnership To Accelerate The Rise Of Smart & Green Cities Across Thailand And Southeast Asia

SciSparc Receives FDA Approval To Initiate Phase IIb Clinical Trial Of SCI-110 In Tourette Syndrome Treatment

U.S. stocks settled higher on Friday, with the Dow Jones index settling at a record high during the session. The US Federal Reserve, on Wednesday, slashed interest rates by 50 basis points Wednesday at its September Federal Open Market Committee meeting, lowering the federal funds rate to a range of 4.75% to 5%.
All three major indices recorded weekly gains, with the S&amp;P 500 gaining around 1.4% and adding more than 19% in 2024. The Dow gained around 1.6% last week, while the tech-heavy Nasdaq jumped around 1.5% during the week.
Wall Street analysts make new stock picks on a daily basis. Unfortunately for investors, not all analysts have particularly impressive track records at predicting market movements. Even when it comes to one single stock, analyst ratings and price targets can vary widely, leaving investors confused about which analyst&#8217;s opinion to trust.
Benzinga&#8217;s Analyst Ratings API is a collection of the highest-quality stock ratings curated by the Benzinga news desk via direct partnerships with major sell-side banks. Benzinga displays overnight ratings changes on a daily basis three hours prior to the U.S. equity market opening. Data specialists at investment dashboard provider Toggle.ai recently uncovered that the analyst insights Benzinga Pro subscribers and Benzinga readers regularly receive can successfully be used as trading indicators to outperform the stock market.
Top Analyst Picks: Fortunately, any Benzinga reader can access the latest analyst ratings on the <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">Analyst Stock Ratings</a> page. One of the ways traders can sort through Benzinga&#8217;s extensive database of analyst ratings is by analyst accuracy. Here&#8217;s a look at the most recent stock picks from each of the five most accurate Wall Street analysts, according to Benzinga <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock</a> Ratings.
Analyst: Zachary Fadem
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 87%</li>
<li>Latest Rating: Maintained an Equal-Weight rating on Darden Restaurants, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DRI#NYSE">DRI</a>) and raised the price target from $160 to $165 on Sept. 20. This analyst sees around 3% downside in the stock.</li>
<li>Recent News: On Sept. 19, Darden Restaurants reported weaker-than-expected first-quarter financial results.</li>
</ul>
Analyst: Sam Reid
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Overweight rating on Ferguson Enterprises Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) and cut the price target from $250 to $225 on Sept. 18. This analyst sees around 13% upside in the stock.</li>
<li>Recent News: On Sept. 17, the company reported net sales of $7.946 billion, which was 1.4% higher year over year, missing the consensus of $7.993 billion.</li>
</ul>
Analyst: Mark Hughes
<ul>
<li>Analyst Firm: Truist Securities</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained a Hold rating on Arthur J. Gallagher &amp; Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AJG#NYSE">AJG</a>) and raised the price target from $265 to $275 on Sept. 20. This analyst sees around 0.4% downside in the stock.</li>
<li>Recent News: On July 25, Arthur J. Gallagher reported better-than-expected second-quarter revenue results.</li>
</ul>
Analyst: Josh Sullivan
<ul>
<li>Analyst Firm: Benchmark</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Reiterated a Buy rating on Intuitive Machines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUNR#NASDAQ">LUNR</a>) with a price target of $10 on Sept. 18. This analyst sees more than 9% gain in the stock.</li>
<li>Recent News: On Sept. 17, Intuitive Machines announced it was awarded a NASA Near Space Network contract for communication and navigation services, with a maximum potential value of $4.82 billion.</li>
</ul>
Analyst: Aaron Raker
<ul>
<li>Analyst Firm: Wells Fargo</li>
<li>Ratings Accuracy: 85%</li>
<li>Latest Rating: Maintained an Overweight rating on Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) and cut the price target from $190 to $175 on Sept. 18. This analyst sees around 92% upside in the stock.</li>
<li>Recent News: On Sept. 17, Micron announced the availability of the Crucial P310 2280 Gen4 NVMe solid-state drive (SSD) which expands Micron's P310 portfolio to address PCs, laptops and PlayStation 5. The company said a version with a heatsink will be released in the coming months, suited for use with PlayStation 5 and desktop gaming PCs.</li>
</ul>
Read More:<a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in"> </a>
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in">Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

Price Target

Pre-Market Outlook

Analyst Ratings

FERG

LUNR

This Analyst With 85% Accuracy Rate Sees Around 92% Upside In Micron - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts

U.S. stock futures were higher this morning, with the Nasdaq futures gaining around 50 points on Monday.
Shares of Jin Medical International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) fell sharply in today's pre-market trading after jumping around 55% on Friday.
Jin Medical International shares dipped 23.5% to $3.12 in pre-market trading.
Here are some big stocks recording losses in today's pre-market trading session.
<ul>
<li>Jin Medical International Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZJYL#NASDAQ">ZJYL</a>) shares dipped 21.5% to $3.20 in pre-market trading after jumping around 55% on Friday.</li>
<li>Primega Group Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PGHL#NASDAQ">PGHL</a>) shares declined 10.3% to $15.00 in pre-market trading after gaining more than 5% on Friday.</li>
<li>James Hardie Industries plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JHX#NYSE">JHX</a>) shares slipped 6% to $39.49 in pre-market trading after gaining more than 8% on Friday.</li>
<li>Korea Electric Power Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KEP#NYSE">KEP</a>) shares declined 5.4% to $7.77 in pre-market trading.</li>
<li>Genmab A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) shares fell 4.3% to $24.44 in pre-market trading after declining around 4% on Friday.</li>
<li>Rezolve AI Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) shares declined 4.1% to $6.10 in pre-market trading following a 9% decline on Friday.</li>
<li>NIO Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) shares fell 2.8% to $5.13 in pre-market trading after declining over 2% on Monday.</li>
</ul>
Now Read This:
<ul>
<li><a href="https://www.benzinga.com/markets/24/09/40962695/jim-cramer-viking-has-many-ships-coming-in"> Jim Cramer: Viking Has &#8216;Many Ships Coming In&#8217;</a></li>
</ul>

Movers

GMAB

PGHL

RZLV

ZJYL

Jin Medical International, Nio And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Benchmark analyst Mike Hickey reiterates Electronic Arts (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EA#NASDAQ">EA</a>) with a Buy and maintains $163 price target.

Reiteration

Benchmark Reiterates Buy on Electronic Arts, Maintains $163 Price Target

On Saturday, the FDA approved Sanofi&#8217;s SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>) Sarclisa (siltuximab) in combination with bortezomib, lenalidomide, and dexamethasone (VRd) as a first-line treatment option for adult patients with newly diagnosed multiple myeloma (NDMM) who are not eligible for autologous stem cell transplant (ASCT).
Also Read: <a target="_blank" href="https://www.benzinga.com/general/biotech/24/09/40957635/sanofis-tolebrutinib-delays-disability-progression-in-patients-with-multiple-sclerosis-data-shows" rel="noreferrer noopener">Sanofi&#8217;s Tolebrutinib Delays Disability Progression In Patients With Multiple Sclerosis, Data Shows</a>.
Sarclisa is the first anti-CD38 therapy in combination with standard-of-care VRd to significantly reduce disease progression or death (by 40%) compared to VRd alone for patients with NDMM not eligible for transplant.
This <a target="_blank" href="https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-20-22-36-34-2949916" rel="noreferrer noopener">decision </a>marks the third approved indication for Sarclisa in the U.S. and the first approved indication in newly diagnosed patients.
The FDA evaluated Sarclisa for this indication under Priority Review, which is reserved for medicines that represent potentially significant improvements in efficacy or safety in treating serious conditions.
Sarclisa is also currently approved in more than 50 countries across two indications for people with relapsed or refractory disease.
The FDA approval is based on data from the IMROZ phase 3 study.
Sarclisa-VRd followed by Sarclisa-Rd met the primary endpoint of PFS, significantly reducing the risk of recurrence or death by 40%, compared to VRd followed by Rd.
At a median follow-up of 59.7 months, the median PFS with the Sarclisa-VRd combination was not reached versus 54.3 months with VRd. The&nbsp;estimated PFS rate at 60 months was 63.2% for patients treated with Sarclisa-VRd&nbsp;versus 45.2% for VRd.
Sarclisa-VRd also met several secondary endpoints which demonstrated deep responses in this patient population:
<ul>
<li>Approximately three-quarters (74.7%) of patients treated with Sarclisa-VRd achieved a complete response (CR) or better than 64.1% of patients taking VRd.</li>
<li>More than half (55.5%) of patients treated with Sarclisa-VRd achieved MRD negative CR compared to 40.9% of patients taking VRd.</li>
</ul>
Price Action: At last check on Monday, SNY stock was down 0.50% at $57.34 during the premarket session.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/09/40976214/totalenergies-and-air-france-klm-double-down-on-sustainability-saf-deal-paves-the-way-to-carbon-" target="_blank" rel="noreferrer noopener">TotalEnergies And Air France-KLM Double Down On Sustainability: SAF Deal Paves The Way To Carbon-Free Skies</a>.</li>
</ul>
Image by HJBC via Shutterstock

Large Cap

Health Care

Sanofi's Sarclisa Secures FDA Approval For First-Line Multiple Myeloma, Marking Its Third US Approval

Last week, a U.S. Geological Survey (USGS) study found that nearly half the United States lies in potential landslide zones. The findings come from a newly released nationwide landslide susceptibility map, offering a county-by-county analysis of landslide risks nationwide.
The map, a product of advanced data analysis and high-resolution elevation data, shows that roughly 44% of U.S. territory could experience landslide activity. For millions of Americans, their homes and communities may be more vulnerable to destructive geological events than previously thought.
Don't Miss:
<ul>
<li>Miami is expected to take New York's place as the U.S. Financial Capital.<a href="https://www.benzinga.com/money/miami-take-new-yorks-place-financial-capital"> Here's how you can invest in the city before that happens</a>.</li>
<li>This Jeff Bezos-backed startup will allow you to<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> become a landlord in just 10 minutes, and you only need $100</a>.</li>
</ul>
Benjamin Mirus, a research geologist with the USGS who worked on the project, said, &#8220;This new national landslide susceptibility map addresses an important but difficult question: which areas across the entire U.S. are prone to landslides?&#8221; The detailed assessment aims to support risk-reduction efforts and inform land-use planning in potentially unstable areas.
The map&#8217;s creation involved analyzing an inventory of nearly one million previous landslides, utilizing high-resolution national elevation data from the USGS 3D Elevation Program. The approach resulted in a far more detailed picture of landslide risk than was previously available, covering known high-risk areas and regions where landslide potential was poorly understood.
Trending: During market downturns, investors are learning that unlike equities, these<a href="https://www.benzinga.com/money/connect-invest-real-estate-notes"> high-yield real estate notes that pay 7.5% &#8211; 9% are protected by resilient assets, buffering against losses.</a>
Certain regions stand out as particularly susceptible. Parts of Appalachia, including West Virginia and eastern Kentucky, show high landslide risks. The Rocky Mountains, California coast and southeast Alaska also prominently in the high-risk category. Over 90% of Puerto Rico is classified as having high landslide susceptibility.
The map&#8217;s release comes just after a sudden landslide in Ketchikan, Alaska, which resulted in one fatality and three injuries, according to the New York Times. <a href="https://www.benzinga.com/topic/climate-change">Climate change is worsening the risks</a> as heavy rainfall events – the primary trigger for landslides – are <a href="https://www.benzinga.com/markets/emerging-markets/23/12/36113247/wind-climate-change-and-the-future">becoming more frequent and intense due to global warming</a>. 
Trending: Will the surge continue or decline on real estate prices?<a href="https://www.benzinga.com/money/realbricks"> People are finding out about risk-free real estate investing that lets you cash out whenever you want.</a>
 The map offers insights into preparedness for homeowners and communities in high-risk areas and highlights regions where further landslide mapping and research are needed. The map presents a broad view of landslide susceptibility but does not predict specific events or their timing. Instead, it offers a probability-based assessment of areas more prone to landslides based on geological and topographical factors.
The USGS advises several precautionary measures for individuals residing in high-risk regions, including staying informed about local geology, monitoring warning signs like wall cracks and tilting trees, and maintaining an emergency plan. In certain situations, property owners may consider consulting engineering geologists for evaluations.
Read Next:
<ul>
<li>Mark Cuban believes &#8220;the next wave of revenue generation is around real estate and entertainment&#8221; —<a href="https://www.benzinga.com/money/bezos-landlord-100-dollars"> this new real estate fund allows you to get started with just $100.</a></li>
<li>A billion-dollar investment strategy with minimums as low as $10 —<a href="https://www.benzinga.com/money/fundrise-flagship-fund"> you can become part of the next big real estate boom today.</a></li>
</ul>

Real Estate

Landslide Danger Looms For 44% Of U.S. Homes – Is Your Property In The Red Zone?

Advanced mobile assistant intended to amplify business operations and customer engagements powered by multi-modal AI workflows
CHARLOTTE, N.C., Sept. 23, 2024 /PRNewswire/ -- Honeywell&nbsp;(NASDAQ:<a href="https://www.benzinga.com/stock/HON#NASDAQ">HON</a>) today announced that it is working to develop an artificial intelligence (AI)-enabled Multi-Modal Intelligent Agent for Honeywell mobile devices powered by Qualcomm Technologies, Inc. The agent will allow workers and customers in the distribution center and retail industries to interact naturally with their handheld devices through voice, pictures, and barcodes.
This AI-powered solution is built to function as a digital resource for the modern labor force and designed to enable today's stretched workforce to quickly tap into answers and outcomes, helping result in time savings, greater accuracy, and interactive results. The design and development of the Multi-Modal Intelligent Agent also supports Honeywell's alignment of its portfolio to three <a href="https://www.honeywell.com/us/en/press/2023/10/honeywell-to-realign-portfolio-to-three-powerful-megatrends-automation-future-of-aviation-and-energy-transition?utm_source=pressrelease&amp;utm_medium=pr&amp;utm_campaign=24-ess-am-ww-pr-701Hu000002MRT6IAO&amp;utm_content=prelease">compelling megatrends</a>, including automation.

QCOM

Honeywell To Develop AI-Enabled Agent Powered By Qualcomm

ASMB

Assembly Biosciences Reports Interim Phase 1a Results From Trial Evaluating Long-Acting Helicase-Primase Inhibitor Candidate ABI-5366; Says ABI-5366 Was Well Tolerated, Half-Life Of ~20 Days Supports Once-Weekly Or Once-Monthly Oral Dosing

Fed's Kashkari Said 50 Basis Point Fed Rate Cut Was Meaningful Step To Get Process Moving;  Expects Smaller Steps Going Forward For Fed

<ul>
<li>New TCT agreements contribute to supporting America's clean energy transition through tax credit transferability under the Inflation Reduction Act (IRA).</li>
<li>Projects are helping to pave the way for additional investments from the voluntary market to support developers fostering renewable energy projects.</li>
<li>Through strategic guidance from Schneider Electric, Kimberly-Clark will fund four new battery energy storage projects, demonstrating its support of critical grid resiliency.</li>
</ul>
BOSTON, Sept. 23, 2024 /PRNewswire/ -- <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260781-1&amp;h=1845358604&amp;u=https%3A%2F%2Fwww.se.com%2Fus%2Fen%2F&amp;a=Schneider+Electric">Schneider Electric</a>,&nbsp;the global leader in the digital transformation of energy management and automation, today announced having facilitated several new TCT deals by <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260781-1&amp;h=3439761111&amp;u=https%3A%2F%2Fwww.kimberly-clark.com%2Fen-us&amp;a=Kimberly-Clark">Kimberly-Clark</a> Corporation, one of the world's leading manufacturers of personal care and hygiene products and owner of household brands such as Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, and WypAll.
Since 2016, Schneider Electric has served as a strategic advisor to Kimberly-Clark in the manufacturer's ambitious decarbonization goals. These include a commitment to reduce absolute GHG emissions by 50% (1) by 2030 and progressing towards 100% renewable electricity in North America by 2030.
Most recently, Schneider Electric acted as a strategic advisor to Kimberly-Clark to help fund multiple battery energy storage projects as part of the rapid energy transition to green America's grid. These TCT deals represent one of the many approaches Kimberly-Clark is taking to advance sustainable solutions. The projects also serve as leading examples of how the voluntary market can support developers fostering key projects using the IRA's new tax credit transferability mechanism.
The work on these collective projects supports the advancement of battery energy storage in the Texas, USA, region, aligned with Kimberly-Clark's support of the green transition in renewable energy storage and generation. Kimberly-Clark's current vPPAs produce clean power from wind in Texas, which makes up <a href="https://c212.net/c/link/?t=0&amp;l=en&amp;o=4260781-1&amp;h=320883471&amp;u=https%3A%2F%2Fwww.epa.gov%2Fgreenpower%2Fgreen-power-partnership-national-top-100&amp;a=40%25+of+its+total+electricity+use+by+U.S.+operations+in+renewable+energy">40% of its total electricity use by U.S. operations in renewable energy</a> that Schneider Electric has advised on.
Details of the new Investment Tax Credit Transfer agreements include:
<ul>
<li>A $82.5M TCT agreement, a 180 MW battery energy storage facility</li>
<li>A $68M TCT agreement, a 100 MW battery energy storage facility</li>
<li>A $55M TCT agreement, a 100 MW battery energy storage project
<ul>
<li>A $32M TCT agreement, a 100MW battery energy storage facility</li>
</ul>
</li>
</ul>

Schneider Electric & Kimberly-Clark Announce Tax Credit Transfer Agreements To Advance Grid Resiliency

MBRX

Moleculin Biotech Presents Data On Annamycin At IASLC 2024, Showing Significant Tumor Growth Inhibition And Extended Survival In Lung Cancer Models With 100% Non-Cardiotoxicity

Morgan Stanley analyst Stephen Byrd maintains Vistra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VST#NYSE">VST</a>) with a Overweight and raises the price target from $110 to $132.

Morgan Stanley Maintains Overweight on Vistra, Raises Price Target to $132

Minneapolis Fed President Kashkari Said Labor Market Strong, Want To Keep It That Way; Won't Declare Mission Accomplished On Inflation

– Results Indicate that FNAIT Risk is More Prevalent Than Previously Estimated –
Rallybio Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RLYB#NASDAQ">RLYB</a>), a clinical-stage biotechnology company translating scientific advances into transformative therapies for patients with devastating rare diseases, announced today that full data from an epidemiological analysis quantifying the proportion of women across diverse populations at higher risk of a fetal and neonatal alloimmune thrombocytopenia (FNAIT)-impacted pregnancy will be presented at the American Society of Human Genetics (ASHG) 2024 Annual Meeting to be held November 5 – 9, 2024 in Denver, CO.

RLYB

Rallybio To Present Results Of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially And Ethnically Diverse Populations At The ASHG 2024 Annual Meeting

Favo Capital expands global footprint with three strategic acquisitions

Press Releases

Favo Capital, Inc, Lands a Substantial Investment from a Leading International Pension Fund

Favo Capital Expands Global Footprint With Three Strategic Acquisitions

FAVO Capital, Inc. Opens A Second Call Centre Location in Dominican Republic and Continues to Implement its Growth Strategy

FAVO Capital, Inc Welcomes Glen Steward as Chief Strategy Officer

FAVO Capital & Stewards Investment Capital Win Prestigious Global Finance Award

FAVO Capital & Stewards Investment Capital Win Structured Finance Deal of the Year at Global Private Banking Innovation Awards 2024

FAVO Capital, Inc. Appoints Turner, Stone & Company, LLP as Auditors

FAVO Capital Engages Investment Bank EF Hutton As Lead Underwriter for Its Proposed Nasdaq Uplisting

Favo Capital

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Get Our Top Trade Ideas Delivered Daily - 65% Off Now

Comments

Favo Capital

News

Latest news for Favo Capital (OTC:FAVO) Stock

Friday, November 29, 2019